TScan Therapeutics Inc. Common Stock TCRX · Stock Open TScan Therapeutics Inc. Common Stock in new tab
TScan Therapeutics Inc. Common Stock Analysis (TCRX)
Is TScan Therapeutics Inc. Common Stock a good investment? TScan Therapeutics Inc. Common Stock (TCRX) is currently trading at 0.3306 USD. Market analysts have a consensus price target of 2.67 USD. This suggests a potential upside from current levels.
Earnings Schedule: TScan Therapeutics Inc. Common Stock is expected to release its next earnings report on Nov. 11, 2026. The market consensus estimate for Forward EPS is -0.57.
Investor FAQ
Does TScan Therapeutics Inc. Common Stock pay a dividend?
No, it does not currently pay a dividend.
What asset class is TScan Therapeutics Inc. Common Stock?
TScan Therapeutics Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Nov. 11, 2026. The company currently has a trailing EPS of -0.90.
Company Profile
TScan Therapeutics, Inc., a clinical-stage biotechnology company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product is TSC-101, for the treatment of patients with acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and acute lymphoblastic leukemia (ALL) in patients undergoing allogeneic hematopoietic cell transplantation (HCT), which is in Phase I clinical trial, as well as eliminates residual disease and promotes donor chimerism. It also develops TSC-102-A01 and TSC-102-A03, which are allogeneic and donor-derived TCR-T therapy candidates targeting epitopes. In addition, the company develops TSC-200, TSC-201, TSC-202, TSC-203, and TSC-204 for the treatment of solid tumors. It has a research collaboration and license agreement with Amgen Inc. to identify antigens recognized by T cells in patients with Crohn's disease. TScan Therapeutics, Inc. was incorporated in 2018 and is headquartered in Waltham, Massachusetts.
Community Discussion